Search Result

Results for "

vancomycin resistant

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (15) Bacterial (42) Carbonic Anhydrase (1) Drug Metabolite (1) Fungal (2) Na+/K+ ATPase (1) Reference Standards (1) SHMT (1)
By Research Areas:	Cancer (1) Infection (37) Inflammation/Immunology (6) Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N14316

Hongoquercin B	Antibiotic Bacterial	Infection
Hongoquercin B is a sesquiterpene antibiotic. Hongoquercin B is only resistant to Vancomycin-resistant Enterococcus faecium at high concentrations .

HY-156198

Bottromycin A2	Antibiotic Bacterial	Infection
Bottromycin A2 is a natural antibiotic. Bottromycin A2 is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) .

HY-N14706

Kibdelin A	Bacterial	Infection
Kibdelin A is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .

HY-121000

Albocycline Ingramycin	Antibiotic Bacterial	Infection
Albocycline (Ingramycin) is a macrolide antibiotic, which exhibits antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin (HY-B0671)-intermediate (VISA), and Vancomycin (HY-B0671)-resistant S. aureus (VRSA) strains with MICs ranging from 0.5 to 1.0 μg/mL. Albocycline exhibits no toxicity to human cells at concentration of ≤64 μg/mL .

HY-N14707

Kibdelin B	Bacterial	Infection
Kibdelin B is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .

HY-N14710

Kibdelin D	Bacterial	Infection
Kibdelin D is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .

HY-N14709

Kibdelin C2	Bacterial	Infection
Kibdelin C2 is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .

HY-P5204

Enterocin Hybrid 1 K1-EJ hybrid	Bacterial	Infection
Enterocin Hybrid 1 is a antibacterial agent, a antibacterial composition. Enterocin Hybrid 1 inhibits Vancomycin (HY-B0671)-resistant E. faecium, Staphylococcus haemoliticus .

HY-N14708

Kibdelin C1	Bacterial	Infection
Kibdelin C1 is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .

HY-176750

HMRZ-62	Bacterial	Infection
HMRZ-62 is an antibacterial agent. HMRZ-62 exhibits antibacterial activity against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) and Vancomycin (HY-B0671)-resistant Enterococcus faecalis (VRE) .

HY-174273

Antibacterial agent 280	Bacterial	Infection
Antibacterial agent 280 (Compound 7af) is an antibacterial agent targeting methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). Antibacterial agent 280 is promising for research of is promising for research of S. aureus infections .

HY-P3078

Amphomycin	Bacterial Antibiotic	Infection
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .

HY-14849

PTZ601 Razupenem; SM 216601; SMP 601	Antibiotic Bacterial	Others
PTZ601 (SMP 601) is an antibiotic, which inhibits the gram-positive bacteria, including the Vancomycin (HY-B0671)-resistant Enterococcus faecium (VREF) and Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). PTZ601 exhibits antimicrobial activity in infected mouse models .

HY-N14899

Oxasetin	Bacterial	Infection
Oxasetin has medium activity against Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococcus faecalis (MIC is 16 μg/mL). Oxasetin has no activity against Gram-negative bacteria and fungi .

HY-N10765

Salvinolone	Bacterial	Inflammation/Immunology Cancer
Salvinolone is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus* (VRE).* Salvinolone shows cytotoxic activity with an IC₅₀ of 47.6 μM against the HL-60 tumor cell line for 72 h .

HY-N15019

Glycothiohexide α	Antibiotic Bacterial	Infection
Glycothiohexide α is a peptide antibiotic. Glycothiohexide α has strong activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VREF), MIC values of 0.03-0.06 μg/mL .

HY-N14171

Epicorazine A	Bacterial Fungal	Infection
Epicorazine A has activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE), MICs of 12.5-25 μg/mL. Epicorazine A also has effect on Candida albicans with a MIC of 25 μg/mL .

HY-134978

(Rac)-SHIN2 2 Publications Verification	SHMT Bacterial	Others
(Rac)-SHIN2 is a pyrazolopyran derivative and a serine hydroxymethyltransferase (SHMT) inhibitor. (Rac)-SHIN2 has antibacterial activity and low cytotoxicity against Hep2 cells. (Rac)-SHIN2 exerts potent antibacterial activity against both vancomycin-susceptible and vanA-type vancomycin-resistant Enterococcus .

HY-N14172

Epicorazine B	Bacterial Fungal	Infection
Epicorazine B has activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE), MICs of 12.5-25 μg/mL. Epicorazine B also has effect on Candida albicans with a MIC of 25 μg/mL .

HY-A0279

Pristinamycin Pristinamycine	Bacterial Antibiotic	Infection
Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF) .

HY-125745

Loloatin B 10	Antibiotic Bacterial	Infection
Loloatin B 10 is an antibiotic, which exhibits antibacterial efficacy against gram positive antibiotic resistant human pathogens .

HY-106574

Ceftobiprole medocaril BAL5788	Bacterial	Infection Inflammation/Immunology
Ceftobiprole medocaril (BAL5788) is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens .

HY-106574A

Ceftobiprole medocaril sodium BAL5788 sodium	Bacterial	Infection Inflammation/Immunology
Ceftobiprole medocaril (BAL5788) sodium is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens .

HY-143326

Antibacterial agent 83	Bacterial	Infection
Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .

HY-112959

Telavancin TD-6424	Antibiotic Bacterial	Infection
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria .

HY-173225

MRSA/VRE-IN-1	Bacterial	Infection
MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .

HY-178056

Carbonic anhydrase-IN-2	Carbonic Anhydrase Bacterial	Infection
Carbonic anhydrase-IN-2 is an orally active carbonic anhydrase inhibitor. Carbonic anhydrase-IN-2 shows antibacterial effect against various vancomycin-resistant Enterococcus (VRE) strains. Carbonic anhydrase-IN-2 can be used for the research of infection, such as E. faecium .

HY-112579

Ceftobiprole 2 Publications Verification Ro 63-9141; BAL 9141	Bacterial Antibiotic	Infection Inflammation/Immunology
Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC₉₀ value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens. Ceftobiprole can be used for the study of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia .

HY-146811

HSGN-94	Bacterial	Inflammation/Immunology
HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .

HY-W436428

V-161	Na+/K+ ATPase Bacterial	Infection
V-161 is the orally active inhibitor for Na ⁺-V-ATPase with an IC₅₀ of 144 nM. V-161 inhibits Enterococcus hirae and Vancomycin-resistant Enterococcus faecium (VRE) under alkaline condition with MIC of 4 µg/mL and 4 µg/mL. V-161 inhibits colonization of VRE in mouse small intestine .

HY-161263

Antibacterial agent 182	Bacterial	Infection
Antibacterial agent 182 (compound 8c) is an antibacterial agent that shows antibacterial activity against various Gram-positive bacteria, particularly against Vancomycin-resistant Enterococcus faecalis (MIC ≤0.125 μg/mL). Antibacterial agent 182 inhibits biofilm formation of Staphylococcus aureus and Pseudomonas aeruginosa at sub-MIC doses .

HY-N16446

Stromemycin	Bacterial	Infection
Stromemycin is a stromelysin inhibitor. Stromemycin exhibits weak antibacterial activity against Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and Bacillus subtilis when used alone. Stromemycin shows a significant increase in antibacterial efficacy when combined with Compound 5. Stromemycin does not possess a significant cell-killing effect on HCT-116 cells .

HY-133119

PK150	Bacterial	Infection
PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 μM, respectively .

HY-16485

Telavancin hydrochloride 1 Publications Verification TD-6424 hydrochloride	Antibiotic Bacterial	Infection
Telavancin hydrochloride is the hydrochloride form of Telavancin (HY-112959). Telavancin hydrochloride is a semisynthetic derivative of vancomycin, and exhibits antibacterial efficacy through inhibition of cell wall synthesis and disruption of cell membrane barrier function. Telavancin hydrochloride is efficient against antibiotic resistant S. aureus strains MRSA, VISA, and hVISA. Telavancin hydrochloride attenuates gram positive bacteria induced complicated skin and skin structure infections (cSSSI) .

HY-69174

1-Amino-2,5-anhydro-1-deoxy-D-mannitol	Bacterial
1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.

HY-116863

KKL-40	Bacterial	Infection
KKL-40 is a small molecule inhibitor that targets the trans-transcription process and is effective against methicillin-sensitive and -resistant Staphylococcus aureus (S. aureus) as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 synergizes with the human antimicrobial peptide LL-37 to inhibit S. aureus, but does not synergize with other antibiotics such as daptomycin, kanamycin, or erythromycin. Trans-transcription is an extreme form of recoding, and KKL-40 inhibits trans-transcription but is nontoxic to HeLa cells .

HY-117845

Citreamicin alpha LL-E19085α	Bacterial Antibiotic	Infection
Citreamicin alpha (LL-E 19085-alpha) is an antibiotic whose in vitro antimicrobial activity against 429 clinical isolates of Gram-positive cocci has been tested by the agar dilution method. These microorganisms included 313 strains of Staphylococci and 116 strains of Streptococci. The in vitro activity of Citreamicin alpha was compared with that of ampicillin, amoxicillin, ceftriaxone, erythromycin, and vancomycin. For Staphylococci, the MIC values of Citreamicin alpha ranged from 0.12-4.0 μg/ml, and for Streptococcus pyogenes of the genus Streptococcus, it was 0.03-0.12 μg/ml. However, enterococci were relatively resistant, requiring 2.0 μg/ml of the agent to inhibit 64% of the 62 tested strains. The in vitro activity of this antibiotic was much better than that of ampicillin, amoxicillin, ceftriaxone, and erythromycin, but comparable or slightly inferior to that of vancomycin.

HY-10393

Eperezolid PNU-100592	Bacterial Antibiotic	Infection
Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of chloramphenicol (HY-B0239) and lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC₉₀ for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .

HY-161935

6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid	Bacterial	Infection Inflammation/Immunology
6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice .

HY-12770R

Mebeverine alcohol (Standard) Mebeverine metabolite Mebeverine alcohol (Standard)	Reference Standards Drug Metabolite	Neurological Disease
Mebeverine alcohol (Standard) is an analytical standard for Mebeverine alcohol. This product is intended for research and analytical applications. Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of Chloramphenicol (HY-B0239) and Lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .

HY-P11085

WLBU2	Bacterial	Infection
WLBU2 is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .

HY-162775

TST1N-224	Bacterial Antibiotic	Infection
TST1N-224 is a potent response regulator VraRC inhibitor. TST1N-224 can disrupt VraRC-DNA complex formation (IC₅₀=60.2 μM). TST1N-224 exhibits interference with VraRC binding to its cognate DNA through a fast-on-fast-off binding mechanism (K_D=23.4 μM). TST1N-224 predominantly interacts with the α9- and α10-helixes of the DNA-binding domain of VraR. TST1N-224 inhibits the growths of S. aureus (SA; MIC>126 μM), Methicillin-resistant S. aureus (MRSA; MIC>126 μM), and Vancomycin-intermediate S. aureus (VISA; MIC=63 μM). TST1N-224, an antimicrobial agent, evidently enhances the susceptibility of VISA to both Vancomycin (HY-B0671) and Methicillin (HY-B0974) .

HY-N14145

Collinone	Antibiotic Bacterial	Infection
Collinone is a recombinant angular polyketide antibiotic. Collinone shows antibacterial activities for gram-positive bacterial. Collinone shows cytotoxicity .

Cat. No.	Product Name	Type

HY-69174

1-Amino-2,5-anhydro-1-deoxy-D-mannitol	Microbial Culture
1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.

1-Amino-2,5-anhydro-1-deoxy-D-mannitol

Microbial Culture

1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.

Cat. No.	Product Name	Target	Research Area